Danazol treatment of myelodysplastic syndromes
- 12 March 2008
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 77 (4), 502-508
- https://doi.org/10.1111/j.1365-2141.1991.tb08617.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor.JCI Insight, 1988
- Management of myelodysplastic syndromesAmerican Journal Of Medicine, 1986
- Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: inhibition of growth of the patient's malignant monocytoid cloneBlood, 1986
- Danazol Therapy in MyelodysplasiaAnnals of Internal Medicine, 1985
- Danazol Therapy for Autoimmune Hemolytic AnemiaAnnals of Internal Medicine, 1985
- Lymphocyte abnormalities in preleukemia — I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptorsLeukemia Research, 1983
- Danazol for the Treatment of Idiopathic Thrombocytopenic PurpuraNew England Journal of Medicine, 1983
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Modification of normal human myelopoiesis by 12-0 tetradecanoylphorbol- 13-acetate (TPA)Blood, 1981
- Mechanisms of glucocorticosteroid activity in patients with the preleukemic syndrome (hemopoietic dysplasia)Leukemia Research, 1980